Marcotte E R, Chugh A, Mishra R K, Johnson R L
Department of Psychiatry, Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada.
Peptides. 1998;19(2):403-6. doi: 10.1016/s0196-9781(97)00321-5.
3(R)-[(2(S)-Pyrrolidinyl-carbonyl)amino]-2-oxo-1-pyrrolidineacetamide (PAOPA) is a peptidomimetic analog of Pro-Leu-Gly-NH2 (PLG or MIF-1) that has previously been demonstrated to be more potent and efficacious that MIF-1 in enhancing dopamine receptor activity. Given the ability of MIF-1 to protect against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) lesioning in C57 BL/6 mice, the present study was undertaken to evaluate the neuroprotective effect of PAOPA in this model. PAOPA was found to be more potent and efficacious that MIF-1 in sparing dopamine and its metabolite levels following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration. Whether the enhanced neuroprotective effect of PAOPA is due to dopamine receptor stimulation, or a result of reduced oxidative stress through normalization of dopamine turnover, remains to be determined.
3(R)-[(2(S)-吡咯烷基-羰基)氨基]-2-氧代-1-吡咯烷乙酰胺（PAOPA）是脯氨酸-亮氨酸-甘氨酸-酰胺（PLG或MIF-1）的拟肽类似物，先前已证明其在增强多巴胺受体活性方面比MIF-1更有效力和功效。鉴于MIF-1能够保护C57 BL/6小鼠免受1-甲基-4-苯基-1,2,3,6-四氢吡啶（MPTP）损伤，本研究旨在评估PAOPA在此模型中的神经保护作用。发现在给予1-甲基-4-苯基-1,2,3,6-四氢吡啶后，PAOPA在保留多巴胺及其代谢物水平方面比MIF-1更有效力和功效。PAOPA增强的神经保护作用是由于多巴胺受体刺激，还是通过使多巴胺周转正常化而降低氧化应激的结果，仍有待确定。
